Thomas B L Lam, Steven MacLennan, Peter-Paul M Willemse, Malcolm D Mason, Karin Plass, Robert Shepherd, Ruud Baanders, Chris H Bangma, Anders Bjartell, Alberto Bossi, Erik Briers, Alberto Briganti, Karel T Buddingh, James W F Catto, Maurizio Colecchia, Brett W Cox, Marcus G Cumberbatch, Jeff Davies, Niall F Davis, Maria De Santis, Paolo Dell'Oglio, André Deschamps, James F Donaldson, Shin Egawa, Christian D Fankhauser, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Silke Gillessen, Nikolaos Grivas, Tobias Gross, Jeremy P Grummet, Ann M Henry, Alexandre Ingels, Jacques Irani, Michael Lardas, Matthew Liew, Daniel W Lin, Lisa Moris, Muhammad Imran Omar, Karl H Pang, Catherine C Paterson, Raphaële Renard-Penna, Maria J Ribal, Monique J Roobol, Morgan Rouprêt, Olivier Rouvière, Gemma Sancho Pardo, Jonathan Richenberg, Ivo G Schoots, J P Michiel Sedelaar, Phillip Stricker, Derya Tilki, Susanne Vahr Lauridsen, Roderick C N van den Bergh, Thomas Van den Broeck, Theodorus H van der Kwast, Henk G van der Poel, Geert J L H van Leenders, Murali Varma, Philippe D Violette, Christopher J D Wallis, Thomas Wiegel, Karen Wilkinson, Fabio Zattoni, James M O N'Dow, Hendrik Van Poppel, Philip Cornford, Nicolas Mottet
BACKGROUND: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. OBJECTIVE: To develop consensus statements for all domains of DAT. DESIGN, SETTING, AND PARTICIPANTS: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives...
December 2019: European Urology